Showing results (1201-1210 of 1,798) with videos related to

Sort By:
Pageof 180
Mabs|June 17, 2017
Changes to International Nonproprietary Names for antibody therapeutics 2017 and beyond: of mice, men and morePaul W H I Parren, Paul J Carter, Andreas Plückthun
Mabs|May 17, 2017
High-resolution mass spectrometry confirms the presence of a hydroxyproline (Hyp) post-translational modification in the GGGGP linker of an Fc-fusion proteinChris Spahr, Kannan Gunasekaran, Kenneth W Walker, et al.
Mabs|August 1, 2018
Platform development for expression and purification of stable isotope labeled monoclonal antibodies in Escherichia coliPrasad T Reddy, Robert G Brinson, J Todd Hoopes, et al.
Mabs|July 10, 2018
Development of a Target cell-Biologics-Effector cell (TBE) complex-based cell killing model to characterize target cell depletion by T cell redirecting bispecific agentsXiling Jiang, Xi Chen, Thomas J Carpenter, et al.
Mabs|July 12, 2018
Massive parallel screening of phage libraries for the generation of repertoires of human immunomodulatory monoclonal antibodiesEmanuele Sasso, Chiara D'Avino, Margherita Passariello, et al.
Mabs|June 29, 2018
FcγRIIIa-dependent IFN-γ release in whole blood assay is predictive of therapeutic IgG1 antibodies safetyNada S Alakhras, Jiabin Qiu, Guilherme V Rocha, et al.
Mabs|June 30, 2018
Characterization of in vivo biotransformations for trastuzumab emtansine by high-resolution accurate-mass mass spectrometryJintang He, Shang-Fan Yu, Sharon Yee, et al.
Mabs|July 4, 2018
Effects of the FcRn developmental pharmacology on the pharmacokinetics of therapeutic monoclonal IgG antibody in pediatric subjects using minimal physiologically-based pharmacokinetic modellingDeni Hardiansyah, Chee Meng Ng
Mabs|August 22, 2018
Antibody characterization using novel ERLIC-MS/MS-based peptide mappingJing Zhen, John Kim, Ying Zhou, et al.
Mabs|August 22, 2018
T-DM1-resistant cells gain high invasive activity via EGFR and integrin cooperated pathwaysYukinori Endo, Yi Shen, Lamis Abou Youssef, et al.
Pageof 180